Cefuroxime
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Cefuroxime
- Pharmacist Assessment Report
- Cefuroxime: second-generation cephalosporin (beta-lactam antibacterial) → polyclonal hyperviscosity syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cefuroxime: second-generation cephalosporin (beta-lactam antibacterial) → polyclonal hyperviscosity syndrome
One-Sentence Summary
Cefuroxime is a second-generation cephalosporin antibacterial that inhibits bacterial cell wall synthesis. The TxGNN model predicts it may be relevant to polyclonal hyperviscosity syndrome, but no clinical trials and no publications support this prediction, and the proposed link has no plausible mechanistic basis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9976 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Cefuroxime is a beta-lactam antibacterial that inhibits bacterial cell wall synthesis.
Polyclonal hyperviscosity syndrome arises from raised levels of polyclonal immunoglobulins, which thicken the blood. No plausible link was identified between an antibacterial cell wall inhibitor and this condition. The high TxGNN score is likely a model artefact rather than a pharmacological signal. The same score was assigned to a second, equally implausible prediction (hyperamylasemia), which supports this interpretation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11227X | Zinnat | Tablet 250 mg (as axetil) | Not recorded in the local data |
At least one licence is valid and the product is marketed as a single-ingredient oral tablet. The list is complete (1 licence).
Safety Considerations
Label-based warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Drug Interactions: 100 interactions were identified. The ones listed below are rated Moderate:
- Acid-suppressing agents: famotidine, ranitidine, cimetidine, nizatidine, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole
- Antacids: aluminium hydroxide, calcium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide
- Aminoglycosides: kanamycin, neomycin
- Other: balsalazide
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no trials or publications for this disease and no plausible mechanistic link, so the evidence level is L5.
To proceed, the following is needed:
- A credible mechanistic hypothesis connecting cefuroxime to immunoglobulin-driven hyperviscosity
- Any preclinical or clinical data directly studying this condition
- Mechanism of action data and TGA Product Information safety review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.